Pfizer's Xeljanz jumps into ulcerative colitis fray with best-case FDA approval

Xeljanz is on a roll. The Pfizer immunology blockbuster scored a big new approval in psoriatic arthritis last year, and now it has won an FDA green light to treat ulcerative colitis—a big new market that could significantly pad its sales.